* concomitant use of another anticoagulant. * known pregnancy. * known hypersensitivity to sulodexide * the need for hospital care at screening * renal insufficiency with crcl \<30ml/min or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. * blood platelet count \< 30 000/µl * other conditions that are judged to carry an increased risk of bleeding as judged by the investigator elimination criteria: a patient randomized in error (monitoring shows that in- or exclusion criteria have been violated) who never received the trial medication, will be excluded from all analyses the investigator must discontinue study treatment for a given patient at any time for the following reasons: • in case of intolerable serious adverse reactions/events, which are clinically relevant, suspected to be related to trial intervention, and affect the patient´s safety. this will be at the discretion of the investigator.

* concomitant use of another anticoagulant. * known pregnancy. * known hypersensitivity to sulodexide * the need for hospital care at screening * renal insufficiency with crcl \<30ml/min or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. * blood platelet count \< 30 000/µl * other conditions that are judged to carry an increased risk of bleeding as judged by the investigator elimination criteria: a patient randomized in error (monitoring shows that in- or exclusion criteria have been violated) who never received the trial medication, will be excluded from all analyses the investigator must discontinue study treatment for a given patient at any time for the following reasons: • in case of intolerable serious adverse reactions/events, which are clinically relevant, suspected to be related to trial intervention, and affect the patient´s safety. this will be at the discretion of the investigator.

concomitant use of another anticoagulant. known pregnancy. known hypersensitivity to sulodexide the need for hospital care at screening renal insufficiency with crcl <30ml/min or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. blood platelet count < 30 000/µl other conditions that are judged to carry an increased risk of bleeding as judged by the investigator elimination criteria: a patient randomized in error (monitoring shows that in- or exclusion criteria have been violated) who never received the trial medication, will be excluded from all analyses the investigator must discontinue study treatment for a given patient at any time for the following reasons: • in case of intolerable serious adverse reactions/events, which are clinically relevant, suspected to be related to trial intervention, and affect the patient´s safety. this will be at the discretion of the investigator.

concomitant use of another anticoagulant. known pregnancy. known hypersensitivity to sulodexide the need for hospital care at screening renal insufficiency with crcl <30ml/min or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. blood platelet count < 30 000/µl other conditions that are judged to carry an increased risk of bleeding as judged by the investigator elimination criteria: a patient randomized in error (monitoring shows that in- or exclusion criteria have been violated) who never received the trial medication, will be excluded from all analyses the investigator must discontinue study treatment for a given patient at any time for the following reasons: • in case of intolerable serious adverse reactions/events, which are clinically relevant, suspected to be related to trial intervention, and affect the patient´s safety. this will be at the discretion of the investigator.